In addition to the potential of circulating Ang-2 as a prognostic biomarker in sorafenib treatment of advanced HCC patients, recently, three ANGPT2 (Ang-2 gene) rs55633437 single-nucleotide polymorphisms (SNPs) have been identified that correlate with patient survival and response to sorafenib. The gene discussed is ANGPT2; the disease is hepatocellular carcinoma.